Biotechnology Companies in Europe

For supermarkets, food producers, and farmers, we offer modular insect farms that convert food waste into animal feed. Our technology helps reduce emissions, mitigate food waste, and replace deforestation-linked soy.

Through pioneering life science and artificial intelligence, we developed our unique Nuritas MagnifierNπΦ platform that allows us to identify, unlock, clinically test and patent peptides; turning them into powerful and precise ingredients that elevate natural efficacy. We want to empower people to live healthier lives, naturally by making our everyday products healthier, safer, greener and more efficacious. From what we eat, to what we apply to our skin. By translating nature’s wisdom into innovation, together, we can change the life of billions.

Who we are: A collective of entrepreneurs, scientists, and experts dedicated to a sustainable future. What we do: We rear Black Soldier Fly to produce protein, oil, and fertilizer for the feed and agriculture industries. Where we do it: We chose Bulgaria as home to our first industrial-scale production facility; it’s close to vital markets such as Greece, Turkey and Western Europe, as well as offering advantageous labor and business conditions.

Eurofins Genomics is a leading international provider of genomic services, specializing in next-generation sequencing, genotyping, and gene expression analysis. Based in Ebersberg, Germany, we support a diverse range of sectors including pharmaceuticals, diagnostics, agriculture, and research. As part of the Eurofins Scientific Group, a global life science leader with a presence in 61 countries, we leverage our extensive expertise and cutting-edge technology to deliver tailored genomic solutions. Our commitment to quality and precision, combined with our ISO 17025 accreditation, ensures reliable and impactful results for our clients worldwide. We offer a comprehensive portfolio of products and services, from custom oligonucleotide synthesis and gene synthesis to advanced sequencing and bioinformatics analysis, empowering scientific discovery and innovation.

TEK Optima Research is a leading provider of advanced imaging systems and AI-powered software solutions, based in Wimborne, Dorset, UK.

We specialize in designing and manufacturing high-performance hardware and innovative DeepInsight cell fingerprinting technology for the Biotech, Medical, and related microscopic imaging industries. Our solutions enable faster, more accurate results for researchers and clinicians.

TEK Optima Research combines cutting-edge hardware development with sophisticated data analytics and AI to deliver a complete imaging platform. We support a wide range of applications, from drug discovery to clinical diagnostics.

Founded in 2019, we’ve quickly established ourselves as a trusted partner for organizations seeking to push the boundaries of microscopic imaging. We currently employ a team of 5 dedicated professionals, operating from our R&D office and manufacturing facility in Dorset and a secondary R&D office in Durham, NC.

Genomics is a pioneering transatlantic TechBio company based in Oxford, UK, specializing in **genomic prevention** and transforming healthcare through the power of genomics.

We leverage large-scale genetic information to provide accurate, personalized risk estimates for common diseases and cancers, enabling early interventions and tailored screening. Our proprietary algorithms and databases link minute variations across the entire genome to biological measurements and disease outcomes, generating population-level insights for healthcare systems and individual-level risk assessments for clinicians.

Genomics partners with leading life sciences and biotech companies, including Novo Nordisk and Vertex, offering a unique approach to sustainable healthcare. Our team of over 150 experts – including world-leading genomic scientists, computational biologists, and data scientists – is dedicated to bringing subject-leading science to a global audience, ultimately transforming lives.

Cell-Easy developed a unique vision of CDMO dedicated to the production of Cell-based Therapy products, this integrated concept is called CDMAO. Beyond conventional CDMO, Cell-Easy is not only focusing on Development & Manufacturing but we are positioning as a real partner for helping Biotech & Pharma to bridge the gap between preclinical and clinical development with in depth expertise on regulatory process scale-up and analytics. Cell-Easy offers customized process development, process scale-up, cGMP manufacturing and unique analytical services for immune cells (engineered CAR-T, NK, …cells, and non-engineered cells) and adult stem cells (MSCs, iPSCs and Exosomes) in both Immuno-Oncology and Regenerative Medicine fields. Cell-Easy is a trusted partner and brings today the infrastructure and know-how while ensuring your projects are delivered on time and budget. Supported by highly motivated and experienced people in the Cell Therapy field, Cell-Easy is committed to driving service excellence and actively contribute to a “Bench to Bedside” culture, putting the health care of patients at the heart of everything.

Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 treating patients with multi-drug resistant cancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.

Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. Two of Antabio’s programs have received Wellcome Trust Seeding Drug Discovery Awards to date: [i] a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections and [ii] a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the long-term management of chronic respiratory infections. The company’s lead product is expected to enter the clinic in 2019 with a fast track to anticipated marketing approval. Antabio has built a best in class, international team of experts in the field and is currently seeking to raise additional funds to progress its pipeline up to the next value inflection point. Our company is also looking to in-license additional assets focused on Gram-negative antibiotic resistant therapies. Please visit www.antabio.com and follow us on Twitter @antabio

HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. The company is using its innovative cell-state modifying platform to gain novel insights into the biology of long non-coding RNAs (lncRNAs), the ‘dark genomes’ information processing features and ‘source code’. HAYA’s lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, which is a tissue and cell-specific cardiac lncRNA known to play a role in heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the cell-specific treatment of diseases in other tissues, including the lungs and the microenvironment of solid tumor cancers. Headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at JLABS @ San Diego, HAYA is led by a world-class team of experts in programmable and precision RNA-targeted therapeutics and is supported by a strong investor consortium. HAYA’s mission is to identify and develop breakthrough disease-modifying therapeutics with the potential for greater efficacy, safety, and accessibility than existing treatments.

bio-bean is the world’s largest recycler of spent coffee grounds, recycling thousands of tonnes annually into sustainable bio-products. The UK drinks 98 million cups of coffee every day, creating a quarter of a million tonnes of spent coffee grounds every year. Typically, these grounds are sent to landfill where they emit greenhouse gases, including methane. Discarding in landfill is not only damaging to our environment, it is also a costly method of waste disposal for businesses due to the UK government’s landfill tax. Working within the existing logistics infrastructure to collect spent coffee grounds from businesses at every scale, we recycle these grounds into sustainable products for a variety of industries. At bio-bean we’re on a mission to reduce waste, reduce emissions and create a real difference for our world by sustainably innovating through coffee waste. As a B Corp™, sustainability is at the heart of everything we do. We’re in it for the long haul, creating impact built to last. Visit www.bio-bean.com to learn more.

AMPLY Discovery is a drug and nutraceutical discovery company based in Northern Ireland. A spin-out company from Queen's University Belfast, we use machine learning and AI to discover new therapeutic molecules for hard-to-treat diseases. This includes developing new drugs to replace conventional antibiotics and help tackle AMR. Our discovery platform is designed to mine vast biological datasets in silico and validate hundreds of hits in vitro.

We are the first in class pre-clinical translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered targets.

Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer. Our mission is to develop a new drug to treat Glioblastoma Multiforme. We aim to significantly increase life expectancy for patients, improve patient comfort, and generally increase the overall survival rates for GBM patients.

HERA-MI brings AI to improve breast cancer early detection to increase recovery rate and to optimize healthcare treatment for women. Breast Cancer is one of the leading cancer causes among women. However, when diagnosed early, patient can recover in almost 90% of cases. HERA-MI is developing a clinical decision support system based on machine learning and medical imaging processing that will improve breast cancer early detection. The system will enhance diagnosis quality and accuracy while reducing radiologists interpretation time. Moreover HERA-MI solution focuses on patient care improvement. With the more efficient breast cancer screening it allows women to be treated earlier and thus offers them higher chances for recovery.

Our mission at HexagonFab is to unlock the secrets of proteins and their interactions. We want to create the tools that enable anyone to understand how a protein behaves, what its properties are and how it interacts with other molecules, e.g. analysis of binding interactions for QC. Our tools help researchers to develop the medicine of the future, to find the best ways to produce novel biomolecules and to assure that medicine is always safe and efficacious. Our focus lies on convenient tools with high degree of automation and low hands-on time. We are a dynamic, interdisciplinary team working at the intersection of biology, nanotechnology and data science. We value a flat hierarchy, where everyone is encouraged to share their ideas and to follow their passion. We believe it is important to move fast, to make mistakes and then to try again.

We are a precision medicine pioneer in psychiatry based in Munich. Founded in 2010, our privately held biotech company combines the development of machine learning-enabled companion diagnostics with specific therapeutics to personalize the treatment of neuropsychiatric disorders with a focus on depression. Our ultimate goal is to improve the lives of patients by developing highly disruptive solutions for their high unmet medical needs. We strives to reduce not only the immense individual burden, but also the societal impact of these diseases. We develop patented genetic tests and combines those with innovative exclusively in-licensed medications, resulting in precise therapies for depression and other neuropsychiatric disorders.

Healshape is a regenerative medecine project. We aim at developing breast regeneration solutions by 3D bioprinting for women who had mastectomy following breast cancer.

HeartBeat.bio is a VC funded drug discovery company focusing on the development of a high-throughput 3D screening platform for heart failure and cardiomyopathies. Our core technology is based on the world-wide first, self-organizing cardiac organoids (Cardioids) which resemble the human physiology of a human heart chamber in a way that allows for the cost-efficient and large scale in-vitro analysis of crucial clinical parameters associated with various cardiac diseases. The Cardioid-based screening platform has the potential to radically change the current cardiovascular drug discovery paradigm.

In Ovo combines animal welfare and efficiency by offering biotechnological solutions to the poultry industry. We currently focus on a long existing problem in hatcheries: The culling of one day old male chickens. Our solution, a gender screening in the first half of the breeding process, has several advantages. It prevents a lot of stress the chickens experience during the current manual gender sorting process, it reduces the energy consumption and CO2 emission of the hatchery and prevents the need to kill one day old chickens. This way, we make hatcheries more animal friendly and sustainable, and increase the efficiency at the same time.

Building a sustainable future together. Microalgae are able to propose solutions to many challenges of the positive economy. We cultivate them for various applications and animal nutrition in particular.

High density and high resolution graphene intelligent neural systems for central and peripheral Neuroelectronic applications

I-Phyc is a natural solutions company, that harnesses the power of algae to remove phosphorus, ammonia and other contaminants from tertiary water while locking away carbon and creating sustainable products.

InFlectis BioScience is a private clinical stage company aiming at targeting and modulating interactions between proteins involved in key human pathophysiological processes. The company is developing small molecule drugs that specifically target the Integrated Stress Response (ISR). Exploiting the ISR’s natural defense offers tremendous potential for the development of a new class of therapies. Led by InFlectis, this area of research is rapidly advancing, resulting in new treatments under development for a variety of disease affecting the central nervous system (CNS), peripheral nervous system (PNS) and inflammation.

inHEART is committed to delivering the world’s most sophisticated, AI-enabled, digital twin of the heart to advance the care of patients living with cardiac disease. We believe all patients deserve access to world-class expertise that guides and optimizes treatment strategies to support improved clinical outcomes and return patients to full, healthy lives.

WE ARE CREATING THE FUTURE OF HEALTH DISPENDIX provides premium liquid handling technology to scientists and lab technicians around the world, and is creating the future of medicine. Liquid handling technology enables new discoveries in areas such as drug development, diagnostics and synthetic biology. We believe that technological advances and science are made for each other. Good technology simplifies science. DISPENDIX GmbH, the premier provider of noncontact liquid handling solutions in the nano to microliter range, started out in 2016 as a spin-off from the Fraunhofer Institute for Manufacturing Engineering and Automation (IPA) in Stuttgart, Germany. In 2018, DISPENDIX joined the world’s leading bio convergence company BICO, which now encompasses 900+ colleagues and 11 companies, offering a portfolio of technologies, products and services to create the future of health. Part of that portfolio is DISPENDIX’s award winning patented and widely recognized technology, the I.DOT (Immediate Drop-on-demand Technology), which brings intuitive automation, precision and speed to every lab, allowing scientists to optimize liquid handling workflows and accelerate their research in a range of applications.

BDD Pharma combines drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and create new value-added products. Rapid parallel clinical testing with BDD SWIFT significantly reduces the time from product concept to clinical success. Recognizing that one size does not fit all we specialise in providing responsive, flexible and innovative solutions to our customers. Our patented delayed release technology OralogiK provides unrivalled control of drug release at the right place and time. Our clinical division provides a full clinical package, including protocol development, study documentation design and regulatory authority submission, through to close out and production of ICH GCP-compliant clinical study report. We specialise in gamma scintigraphy, a powerful and versatile technology used to investigate the in vivo behaviour of your formulation. Coupled with pharmacokinetic data, this technique can be used to provide information on time /site of disintegration, gastric emptying, GI transit and intra/ inter individual differences.

Dxcover is a clinical stage liquid biopsy company developing tests for the early detection of multiple cancers, when treatment has a better chance to impact outcomes. The company has pioneered the early detection and identification of cancer employing infrared spectroscopy of circulating pan-omic biomarkers. The company has generated compelling clinical data with high accuracy detection of Stage I and Stage II cancers. Dxcover is based in Scotland, United Kingdom and is establishing operations in the USA.

Eagle Genomics applies network science to biology. We are revealing the impact of the microbiome on humans, animals and the environment to secure a sustainable future for our food, water, soil and the health of our planet. Our mission is to deliver insight from the microbiome to profoundly change our understanding of wellness and even our fundamental assumptions about life on earth. Our platform transforms scientists’ journey to insights, unifying constellations of complex, multi-dimensional data (the data fabric) to explore and extract signals and networks of relationship, otherwise not detectable by humans alone. This is the frontier of science today and nowhere are the opportunities and challenges more significant than in the burgeoning field of the microbiome.

StarkAge Therapeutics is a privately-held biotechnology start-up, whose ambition is to delay or halt disease progression and improve quality of life of patients with age-related diseases, associated with senescent cells accumulation. It builds on its unique disease-specific exosomal / EV technology while harnessing immunotherapy approach, to address very large senescence unmet medical needs.

Subitec is a solution provider covering its customers’ needs in leading edge industrial turnkey production plants and related supporting systems based on proprietary Flat Panel Airlift (FPA) photobioreactors-technology. More than twenty years ago Subitec started its activities with a strong focus on better understanding prerequisites and conditions of microalgae and cyanobacteria cultivation. Backed by this research know-how, Subitec nowadays has installed more than 50 production plants and supporting systems equipped with our proprietary FPA photobioreactors all over the world.

Susu's mission is to make healthcare affordable and accessible for Africans, in an integrated approach which connects the beneficiaries of the services, their families, and healthcare professionals. - Our services include care bundles which are packages of curative and preventative services designed to monitor the condition of chronic disease patients and pregnant women. - We also offer insurance services in partnership with insurance providers. - Our offers can be subscribed by African diaspora members on behalf of their loved ones back home

At abcam, we believe the scientific community goes further, faster when we go there together. And to keep on making ground-breaking discoveries, we need to work together in new ways. That’s why we’re constantly innovating to help scientists drive their research forward by providing products and solutions that play an essential role in fundamental research, drug discovery, diagnostic and therapeutic applications. We started with a simple mission: to provide the best biological reagents to life scientists worldwide. Today, we help 750,000 researchers in over 130 countries deliver faster breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders.

Adapttech is a biomedical innovation company committed to bringing new smart technologies to the O&P market. We aim to empower clinicians with data-driven solutions and patient remote monitoring methods to improve the quality of life of lower-limb prosthetic users.

Automata was founded with a clear aim: to unlock human potential with automation. Through our collaboration with some of the world’s leading pathology labs, we’ve developed the most comprehensive lab automation platform on the market. By simplifying environments and empowering people, Automata enables labs to scale with precision and creates new opportunities for scientists to accelerate innovation.

We are Bicycle Therapeutics, a clinical-stage biopharmaceutical company. We didn’t wait for the next advance against cancer. We created it. Based on groundbreaking work conceived in the laboratory of Sir Greg Winter with the help of Professor Christian Heinis, we are pioneering the development of bicyclic peptides, or Bicycles® – a novel class of versatile, chemically synthesized medicines. Bicycles are fully synthetic short peptides constrained to form two loops which stabilize their structural geometry. This constraint is designed to confer high affinity and selectivity, and the relatively large surface area presented by the molecule allows targets to be drugged that have historically been intractable to non-biological approaches. Bicycles represent a unique therapeutic class, combining the pharmacological properties normally associated with a biologic with the manufacturing and pharmacokinetic advantages of a small molecule, yet with no signs of immunogenicity observed to date. Bicycles can be used as Bicycle conjugates to deliver toxin payloads and to precisely target local immune activation within tumors and as Bicycle T-cell modulators, which activate cytotoxic T-cells while circumventing the limitations of antibody and biologic therapies and better enabling combination therapy. Our lead product candidate, BT1718, is a Bicycle toxin conjugate currently being investigated in a Phase I/IIa open label dose escalation and expansion clinical trial sponsored by Cancer Research UK. BT1718 targets Membrane Type 1 Matrix Metalloproteinase (MT1-MMP), also known as MMP-14, which is highly expressed in many solid tumors. Our strategic collaborations are based on the ability of Bicycles to address a wide variety of targets. Through collaborations with AstraZeneca, Oxurion, Innovate UK and the Dementia Discovery Fund, we work with companies that have deep therapeutic expertise outside of oncology to enable us to more efficiently develop novel medicines for patients.

Biorelate helps scientists solving the most difficult biomedical challenges of today. We do this by curating truths from existing knowledge, enabling smarter and faster research & development.

bit.bio is an award-winning human synthetic biology enterprise. Our mission is coding cells for health. To do so, we apply the principles of computation to biology. Our current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. This has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modelling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious and driven by a common purpose.

IRUBIS | Innovative Process Analytical Spectroscopy for Biomanufacturing. IRUBIS is a company that specializes in mid-infrared (MIR) spectroscopy for bioprocessing. We have designed an instrument, Monipa, specifically for bioprocess monitoring and control. Monipa is based on MIR spectroscopy, making it possible to monitor multiple bioprocesses real-time and continuously. Our instrument's applications are foreseen in both upstream and downstream bioprocessing. These include multiple metabolite monitoring and control in upstream processing. In addition, contaminant detection or monitoring of target proteins and excipients can be aided in downstream processing. Read more about our products and innovations at www.irubis.com.

We took telemedicine to a whole new level. Invented the first Precision Medicine platform. And didn't survive the Covid-19 crisis. Thank you. We'll miss you.

Zoono Animal Health UK is an accredited licensee for Zoono Animal Health antimicrobial products, bringing Zoono’s market-leading technology into the UK and European agricultural sector. Our vision is to provide the future of antimicrobial technology with animal health at the forefront. We strive to build productive relationships to make a positive impact on animal health. Our antimicrobial products are; - Proven to protect surfaces for up to 30 days from a single application - Water based, containing no harmful chemicals - Validated extensively by over 150 independent tests worldwide - Protects against 99.99% of known germs - Proven to generate significant Returns on Investment in the agricultural sector

Developing avant-garde computational pathology solutions to streamline pathologist workflows and help deliver personalised medicine.

Neuroelectrics® is a digital brain health company that innovates at the intersection of neuroscience, physics, machine learning, and hardware. We have developed wireless EEG and tDCS/tACS/tRNS stimulation devices with up to 32 channels, amongst other products encompassing software and research services, with the purpose of monitoring and enhancing brain health.

Nightingale Health is a health technology company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. The wide-ranging disease risk predictions provided by Nightingale consist of two interconnected factors: The extensive blood analysis technology developed by Nightingale and a large amount of data on health events. Nightingale helps people make better personal health decisions and connects the health industry to offer their services for individuals' preventative needs. By empowering the world with comprehensive health insights, we accelerate scientific discoveries, industry developments and improve personal health for everyone. We’re a team of 60 members––a diverse bunch with interdisciplinary expertise in business, marketing, computational medicine, data science, healthcare, IT, design and more––who envisage a world that focuses on keeping people healthy rather than just treating illnesses. So, if you are looking to enable good tech that could make a real difference, Nightingale is the place to be.

Innovative polish company offering monitoring wristbands and telemedine platform to hospitals, institutions, idividuals SiDLY initiates the development of medical telematics in Poland and Europe. SiDLY sp.z o.o. as one of the first organizations, deal comprehensively with medical diagnostics from the distance, starting from the search of areas requiring initiating telematics solutions through design, testing and constructing of both- devices and systems, and the dedicated application. SiDLY team, consists of the representatives of technology, medicine and science. The products of SiDLY improve the work of clinics and houses of Social Welfare. They also enable a remote medical diagnostics for individual costumers. Telemedical platform with wristbands is implemented in hospitals, including contagious departures.

Turbine was founded for a simple reason; to understand complex cancers better than existing experimental tools in order to solve unmet oncology needs. Through a multidisciplinary team that unites computer science and molecular biology, and the world's most intricate simulation of cell behavior, we identify treatment options for the 70% of cancers that are currently unexplored. We use our platform, the Simulated Cell™, to uncover novel biological insights across both new and known targets. This allows us to provide a fresh biological context, define responsive patient populations, and design drug combination approaches that diminish resistance. With a process proven by clinical stage predictions and a proprietary pipeline, we continue our mission of unlocking cancer complexity to deliver next-generation precision therapeutics.

Abionic, an in vitro diagnostics (IVD) company, was founded in 2010 as a spin-off from the Swiss Federal Institute of Technology of Lausanne (EPFL). Abionic is aiming to make a difference in patient care through the cutting-edge nanofluidic technology based ultra-rapid diagnostic platform, helping healthcare professionals to make clinical decisions at the point of care.

A new medicine R&D engine (R&D pharma company) operated by an experienced team dedicated to the discovery and development of new medicines to treat patient suffering from severe diseases of the central nervous system. Accure Therapeutics focuses on neurons that suffer a dysfunction, and on the glial environment that supports them, in an attempt to impede their degeneration and death. We work to find new medicines that correct the pathological changes that are responsible for the disease, and that produce beneficial outcomes (i.e. Disease Modifying Therapies). We specialize in developing drugs that promote neuroprotection and neurorepair by integrating the latest advances in neurobiology with state-of-the-art clinical research. We have currently built up a drug candidate portfolio that focuses on four areas: Optic Neuritis, Multiple Sclerosis, Parkinson’s Disease and Epilepsy.

"Innovative medicine for everyone, everywhere" Listed on the Euronext stock market, Adocia is a clinical-stage biotech company specialized in the development of best-in-class medicine relying on innovative formulations of already-approved therapeutic proteins. Adocia operates in the diabetes and metabolic disease field. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients. For more information, visit our website: www.adocia.com For careers offers, please click to the following link : http://offres.adocia.com/en

Affilogic is a private biotech company specialised in discovering and developing Nanofitins® through early-stage collaborations with worldwide industry leaders in the pharmaceutical sector. These affinity proteins are potent antibody-mimetics, exhibiting a high affinity and specificity for capture, targeting and interacting with biomolecules. Each Nanofitin® is 20 times smaller than an antibody (7 kDa) and demonstrates hyper stability. Nanofitins are easily combined with each other, antibodies and other biomolecules by simple, rapid and proven methods to design an ideal targeted molecule. Affilogic has designed Nanofitins® against 60+ targets to date, including a wide range of circulating antigens (peptides, proteins), membrane receptors for inhibition / modulation (GPCR, ion channels) and complex entities (virus-like particles, bacteria, whole cells).